Based on the Bicycle Therapeutics plc stock forecast from 0 analysts, the average analyst target price for Bicycle Therapeutics plc is not available over the next 12 months. Bicycle Therapeutics plc’s average analyst rating is not available. Stock Target Advisor’s own stock analysis of Bicycle Therapeutics plc is Bearish, which is based on 2 positive signals and 6 negative signals. At the last closing, Bicycle Therapeutics plc’s stock price was EUR 13.60. Bicycle Therapeutics plc’s stock price has changed by -7.48% over the past week, -28.04% over the past month and -18.56% over the last year.
No recent analyst target price found for Bicycle Therapeutics plc
No recent average analyst rating found for Bicycle Therapeutics plc
Company Overview Bicycle Therapeutics plc
Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics in the United States and the United Kingdom. Its product pipeline comprising BT8009, a bicycle toxin conjugate (BTC) which is in phase I/II/III clinical trial for the treatment of high nectin-4 expressing tumors; BT5528, a BTC which is in phase I/II clinical trial for the treatment of Ephrin type A receptor 2 expressing tumor; BT7480, a Bicycle TICA molecule which is in phase I/II targeting Nectin-4 and agonizing CD137; and BT7455, a Bicycle TICA molecule targeting Ephrin type A receptor 2 and CD137 and is in preclinical trial. The company also developing BT1718, a bicycle toxin conjugate (BTC), which is in Phase I/IIa clinical trials targeting tumors that express Membrane Type 1 matrix metalloprotease; and BT7401, a multivalent bicycle CD137 agonist which is in phase IIa to treat advanced solid tumors. In addition, it develops Novel anti-infective, which is in preclinical trial targeting anti-infectives disease; CNS targets, which is in preclinical trial targeting CNS disease; and Novel neuromuscular targets, which is in preclinical trial targeting neuromuscular disease. Further, the company collaborates with biopharmaceutical companies and organizations to develop programs in therapeutic areas. It has collaboration and license agreement with Bayer Consumer Care AG; Novartis Pharma AG; Cancer Research UK; Cancer Research Technology Ltd; and Oxurion NV. Bicycle Therapeutics plc was incorporated in 2009 and is headquartered in Cambridge, the United Kingdom. Read Less
Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics in the United States and the United Kingdom. Its product pipeline comprising BT8009, a bicycle toxin conjugate (BTC) whic...Read More
Frequently Asked Questions About Bicycle Therapeutics plc (50BA:F) Stock
Stock Target Advisor's fundamental analysis for Bicycle Therapeutics plc's stock is Bearish.
Unfortunately we do not have enough data on 50BA:F's stock to indicate if its a good dividend stock.
Unfortunately we do not have enough data on 50BA:F's stock to indicate what its average analyst target is.
50BA:F stock's Price/Earning ratio is 1,790.56.
Our analysis grades 50BA:F stock's Price / Earning ratio at F. This means that 50BA:F stock's Price/Earning ratio is above 99% of the stocks in the Biotechnology sector in the F exchange.
Based on this 50BA:F may be a overvalued for its sector.
The last closing price of 50BA:F's stock was EUR 13.60.
The most recent market capitalization for 50BA:F is EUR 1.27B.
Unfortunately we do not have enough analyst data on 50BA:F's stock to indicate whether its price will go up or not.
We can't find any ETFs which contains Bicycle Therapeutics plc's stock.
As per our most recent records Bicycle Therapeutics plc has 284 Employees.
Bicycle Therapeutics plc's registered address is Portway Building, Cambridge, United Kingdom, CB21 6GS.
You can get more information about it from Bicycle Therapeutics plc's website at https://www.bicycletherapeutics.com.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
Low volatility
The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.
High market capitalization
This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.
What not to like
Overpriced compared to earnings
The stock is trading high compared to its peers on a price to earning basis and is above the sector median.
Below median dividend returns
The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.
Poor risk adjusted returns
This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.
Negative cashflow
The company had negative total cash flow in the most recent four quarters.
Negative free cash flow
The company had negative total free cash flow in the most recent four quarters.
Low Earnings Growth
This stock has shown below median earnings growth in the previous 5 years compared to its sector
Frequently Asked Questions About Bicycle Therapeutics plc (50BA:F) Stock
Stock Target Advisor's fundamental analysis for Bicycle Therapeutics plc's stock is Bearish.
Unfortunately we do not have enough data on 50BA:F's stock to indicate if its a good dividend stock.
Unfortunately we do not have enough data on 50BA:F's stock to indicate what its average analyst target is.
50BA:F stock's Price/Earning ratio is 1,790.56.
Our analysis grades 50BA:F stock's Price / Earning ratio at F. This means that 50BA:F stock's Price/Earning ratio is above 99% of the stocks in the Biotechnology sector in the F exchange.
Based on this 50BA:F may be a overvalued for its sector.
The last closing price of 50BA:F's stock was EUR 13.60.
The most recent market capitalization for 50BA:F is EUR 1.27B.
Unfortunately we do not have enough analyst data on 50BA:F's stock to indicate whether its price will go up or not.
We can't find any ETFs which contains Bicycle Therapeutics plc's stock.
As per our most recent records Bicycle Therapeutics plc has 284 Employees.
Bicycle Therapeutics plc's registered address is Portway Building, Cambridge, United Kingdom, CB21 6GS.
You can get more information about it from Bicycle Therapeutics plc's website at https://www.bicycletherapeutics.com.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for 50BA:F !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
